INTRODUCTION: The prognostic 15-gene expression profile (15-GEP) test for uveal melanoma (UM) predicts metastatic risk based on primary tumor biology. Here we report outcomes from a prospective registry of 15-GEP-tested patients, and a meta-analysis with published cohorts. OBJECTIVES: Management and 5-year clinical outcomes following 15-GEP testing were evaluated. METHODS: Eighty-nine patients with 15-GEP results were prospectively enrolled at four centers. Physician-recommended management plans were collected, and clinical outcomes tracked every 6 months. RESULTS: Eighty percent of Class 1 (low-risk) patients underwent low-intensity management; all Class 2 (high-risk) patients underwent high-intensity management (p < 0.0001). Median follow-up for event-free patients was 4.9 years. Five Class 1 (10%) and 23 Class 2 (58%) tumors metastasized (p < 0.0001). Five-year Class 1 and 2 metastasis-free survival rates were 90% (81-100%) and 41% (27-62%; p < 0.0001), and melanoma-specific survival rates were 94% (87-100%) and 63% (49-82%; p = 0.0007). Class 2 was the only independent predictor of metastasis and was associated with increased risk for metastasis and mortality by meta-analysis. CONCLUSIONS: UM patient management is guided by 15-GEP testing. Class 2 patients were managed more intensely, in accordance with an observed metastatic rate of >50%; Class 1 patients were safely spared intensive surveillance, resulting in appropriate utilization of healthcare resources.
INTRODUCTION: The prognostic 15-gene expression profile (15-GEP) test for uveal melanoma (UM) predicts metastatic risk based on primary tumor biology. Here we report outcomes from a prospective registry of 15-GEP-tested patients, and a meta-analysis with published cohorts. OBJECTIVES: Management and 5-year clinical outcomes following 15-GEP testing were evaluated. METHODS: Eighty-nine patients with 15-GEP results were prospectively enrolled at four centers. Physician-recommended management plans were collected, and clinical outcomes tracked every 6 months. RESULTS: Eighty percent of Class 1 (low-risk) patients underwent low-intensity management; all Class 2 (high-risk) patients underwent high-intensity management (p < 0.0001). Median follow-up for event-free patients was 4.9 years. Five Class 1 (10%) and 23 Class 2 (58%) tumors metastasized (p < 0.0001). Five-year Class 1 and 2 metastasis-free survival rates were 90% (81-100%) and 41% (27-62%; p < 0.0001), and melanoma-specific survival rates were 94% (87-100%) and 63% (49-82%; p = 0.0007). Class 2 was the only independent predictor of metastasis and was associated with increased risk for metastasis and mortality by meta-analysis. CONCLUSIONS: UM patient management is guided by 15-GEP testing. Class 2 patients were managed more intensely, in accordance with an observed metastatic rate of >50%; Class 1 patients were safely spared intensive surveillance, resulting in appropriate utilization of healthcare resources.
Authors: Marie Diener-West; Sandra M Reynolds; Donna J Agugliaro; Robert Caldwell; Kristi Cumming; John D Earle; Barbara S Hawkins; James A Hayman; Ishmael Jaiyesimi; Lee M Jampol; John M Kirkwood; Wui-Jin Koh; Dennis M Robertson; John M Shaw; Bradley R Straatsma; Jonni Thoma Journal: Arch Ophthalmol Date: 2005-12
Authors: D Gomez; C Wetherill; J Cheong; L Jones; E Marshall; B Damato; S E Coupland; P Ghaneh; G J Poston; H Z Malik; S W Fenwick Journal: J Surg Oncol Date: 2013-12-19 Impact factor: 3.454
Authors: Michael C Chappell; Devron H Char; Tia B Cole; J William Harbour; Kavita Mishra; Vivian K Weinberg; Theodore L Phillips Journal: Am J Ophthalmol Date: 2012-04-27 Impact factor: 5.258
Authors: Hakan Demirci; Leslie M Niziol; Zeynep Ozkurt; Naziha Slimani; Cem Ozgonul; Tiffany Liu; David C Musch; Miguel Materin Journal: Am J Ophthalmol Date: 2018-08-04 Impact factor: 5.258
Authors: Ernie Marshall; Christopher Romaniuk; Paula Ghaneh; Helen Wong; Marie McKay; Mona Chopra; Sarah E Coupland; Bertil E Damato Journal: Br J Ophthalmol Date: 2012-11-17 Impact factor: 4.638
Authors: April K S Salama; Nicole de Rosa; Randall P Scheri; Scott K Pruitt; James E Herndon; Jennifer Marcello; Douglas S Tyler; Amy P Abernethy Journal: PLoS One Date: 2013-03-13 Impact factor: 3.240
Authors: Katherina M Alsina; Lauren M Sholl; Kyle R Covington; Suzzette M Arnal; Michael A Durante; Christina L Decatur; John F Stone; Kristen M Oelschlager; J William Harbour; Federico A Monzon; Robert W Cook; Sherri Borman Journal: Ocul Oncol Pathol Date: 2021-08-04
Authors: Saman S Ahmadian; Ian J Dryden; Andrea Naranjo; Angus Toland; Romain A Cayrol; Donald E Born; Peter S Egbert; Ryanne A Brown; Prithvi Mruthyunjaya; Jonathan H Lin Journal: Ocul Oncol Pathol Date: 2022-03-11
Authors: Basil K Williams; Jennifer J Siegel; Katherina M Alsina; Lauren Johnston; Amanda Sisco; Kyleigh LiPira; Sara M Selig; Peter G Hovland Journal: Melanoma Manag Date: 2022-09-16